Group 1 - The company MIRXES-B (02629) plans to conduct an initial public offering (IPO) from May 15 to May 20, 2025, with a total of 46.62 million shares being offered globally, where 10% is allocated for Hong Kong and 90% for international markets [1] - The offering price is set at HKD 23.30 per share, with trading expected to commence on May 23, 2025, at 9:00 AM on the Hong Kong Stock Exchange [1] - Founded in 2014 and headquartered in Singapore, the company specializes in microRNA (miRNA) technology, focusing on making disease screening and diagnostic solutions accessible in key Asian markets, including Singapore and China [1] Group 2 - The estimated net proceeds from the global offering, calculated at the offering price of HKD 23.30 per share, will be approximately HKD 880.5 million [2] - The intended use of the net proceeds includes 51% for research and development, regulatory filings, production, and commercialization of the core product GASTROClearTM; 24% for ongoing and planned R&D for pipeline products; 15% to enhance and integrate the company's end-to-end capabilities; and 10% for working capital and general corporate purposes [2] - The company has entered into cornerstone investment agreements with Beijing Xunrui Enterprise Management Partnership (Limited Partnership) and Evergreen Gate Limited, with cornerstone investors agreeing to subscribe for USD 57.92 million under certain conditions [2]

Core Viewpoint - Mirxes Holding Company Limited is seeking to go public through a listing hearing on the Hong Kong Stock Exchange, with CICC and Jianyin International as joint sponsors [1] Company Overview - Mirxes was established in 2014 and is headquartered in Singapore [1] - The company specializes in microRNA (miRNA) technology [1] Product Information - The core product of Mirxes is GASTROClearTM, a blood-based miRNA testing kit for gastric cancer screening [1] - GASTROClearTM consists of 12 miRNA biomarkers [1]

Company Overview - Mirxes Holding Company Limited, founded in 2014 and headquartered in Singapore, specializes in microRNA (miRNA) technology for disease screening and diagnostic solutions in key Asian markets, including Singapore and China [5][6] - The company has one core product, GASTROClear™, and two other commercialized products, LUNGClear™ and Fortitude™, along with six candidates in preclinical stages [5] Product Details - GASTROClear™ is a blood-based miRNA test kit for gastric cancer screening, consisting of 12 miRNA biomarkers. It received regulatory approval from the Health Sciences Authority (HSA) in Singapore in May 2019 and has been successfully commercialized [5][6] - The company is one of the few globally to have regulatory approval for molecular cancer screening IVD products and is the first and only company to receive such approval for molecular gastric cancer screening [5] Market Position - Mirxes operates within the liquid biopsy subcategory of the overall disease screening market, focusing on non-invasive, affordable, and effective blood-based miRNA test kits for early cancer detection [6] - The company’s core product, GASTROClear™, is part of a growing trend in molecular diagnostics, utilizing liquid samples to detect cancer biomarkers [6] Financial Performance - The company reported revenues of approximately $17.76 million, $24.19 million, and $20.28 million for the years 2022, 2023, and 2024, respectively [6][7] - Gross profits for the same years were approximately $9.33 million, $13.58 million, and $8.89 million, indicating a gross margin of 52.5%, 56.2%, and 43.8% respectively [7]